Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 368

1.

Multicenter phase II study of bortezomib in patients with relapsed or refractory mantle cell lymphoma.

Fisher RI, Bernstein SH, Kahl BS, Djulbegovic B, Robertson MJ, de Vos S, Epner E, Krishnan A, Leonard JP, Lonial S, Stadtmauer EA, O'Connor OA, Shi H, Boral AL, Goy A.

J Clin Oncol. 2006 Oct 20;24(30):4867-74. Epub 2006 Sep 25.

2.

Phase II study of proteasome inhibitor bortezomib in relapsed or refractory B-cell non-Hodgkin's lymphoma.

Goy A, Younes A, McLaughlin P, Pro B, Romaguera JE, Hagemeister F, Fayad L, Dang NH, Samaniego F, Wang M, Broglio K, Samuels B, Gilles F, Sarris AH, Hart S, Trehu E, Schenkein D, Cabanillas F, Rodriguez AM.

J Clin Oncol. 2005 Feb 1;23(4):667-75. Epub 2004 Dec 21.

3.

Multicenter randomized phase II study of weekly or twice-weekly bortezomib plus rituximab in patients with relapsed or refractory follicular or marginal-zone B-cell lymphoma.

de Vos S, Goy A, Dakhil SR, Saleh MN, McLaughlin P, Belt R, Flowers CR, Knapp M, Hart L, Patel-Donnelly D, Glenn M, Gregory SA, Holladay C, Zhang T, Boral AL.

J Clin Oncol. 2009 Oct 20;27(30):5023-30. doi: 10.1200/JCO.2008.17.7980. Epub 2009 Sep 21.

4.

Bortezomib for the treatment of mantle cell lymphoma.

Kane RC, Dagher R, Farrell A, Ko CW, Sridhara R, Justice R, Pazdur R.

Clin Cancer Res. 2007 Sep 15;13(18 Pt 1):5291-4.

5.

Safety of prolonged therapy with bortezomib in relapsed or refractory multiple myeloma.

Berenson JR, Jagannath S, Barlogie B, Siegel DT, Alexanian R, Richardson PG, Irwin D, Alsina M, Rajkumar SV, Srkalovic G, Singhal S, Limentani S, Niesvizky R, Esseltine DL, Trehu E, Schenkein DP, Anderson K.

Cancer. 2005 Nov 15;104(10):2141-8.

6.

Results of a phase 2 study of bortezomib in patients with relapsed or refractory indolent lymphoma.

Di Bella N, Taetle R, Kolibaba K, Boyd T, Raju R, Barrera D, Cochran EW Jr, Dien PY, Lyons R, Schlegel PJ, Vukelja SJ, Boston J, Boehm KA, Wang Y, Asmar L.

Blood. 2010 Jan 21;115(3):475-80. doi: 10.1182/blood-2009-08-233155. Epub 2009 Nov 19.

7.

Extended follow-up of a phase II trial in relapsed, refractory multiple myeloma:: final time-to-event results from the SUMMIT trial.

Richardson PG, Barlogie B, Berenson J, Singhal S, Jagannath S, Irwin DH, Rajkumar SV, Srkalovic G, Alsina M, Anderson KC.

Cancer. 2006 Mar 15;106(6):1316-9.

8.

Phase II clinical experience with the novel proteasome inhibitor bortezomib in patients with indolent non-Hodgkin's lymphoma and mantle cell lymphoma.

O'Connor OA, Wright J, Moskowitz C, Muzzy J, MacGregor-Cortelli B, Stubblefield M, Straus D, Portlock C, Hamlin P, Choi E, Dumetrescu O, Esseltine D, Trehu E, Adams J, Schenkein D, Zelenetz AD.

J Clin Oncol. 2005 Feb 1;23(4):676-84. Epub 2004 Dec 21.

9.

A retrospective analysis of bortezomib therapy for Japanese patients with relapsed or refractory multiple myeloma: beta2-microglobulin associated with time to progression.

Ohguchi H, Sugawara T, Ishikawa I, Okuda M, Tomiya Y, Yamamoto J, Onishi Y, Fujiwara Yamada M, Ishizawa K, Kameoka J, Harigae H.

Int J Hematol. 2009 Apr;89(3):342-7. doi: 10.1007/s12185-009-0279-4. Epub 2009 Mar 19.

PMID:
19296199
10.

Patients with chemotherapy-refractory mantle cell lymphoma experience high response rates and identical progression-free survivals compared with patients with relapsed disease following treatment with single agent bortezomib: results of a multicentre Phase 2 clinical trial.

O'Connor OA, Moskowitz C, Portlock C, Hamlin P, Straus D, Dumitrescu O, Sarasohn D, Gonen M, Butos J, Neylon E, Hamelers R, Mac-Gregor Cortelli B, Blumel S, Zelenetz AD, Gordon L, Wright JJ, Vose J, Cooper B, Winter J.

Br J Haematol. 2009 Apr;145(1):34-9. doi: 10.1111/j.1365-2141.2008.07466.x. Epub 2009 Feb 6.

PMID:
19220284
11.

Safety and efficacy of bortezomib in high-risk and elderly patients with relapsed multiple myeloma.

Richardson PG, Sonneveld P, Schuster MW, Irwin D, Stadtmauer EA, Facon T, Harousseau JL, Ben-Yehuda D, Lonial S, San Miguel JF, Cavenagh JD, Anderson KC.

Br J Haematol. 2007 Jun;137(5):429-35. Epub 2007 Apr 19.

PMID:
17451408
12.

Safety and efficacy results from an international expanded access programme to bortezomib for patients with relapsed and/or refractory multiple myeloma: a subset analysis of the Australian and New Zealand data of 111 patients.

Quach H, Horvath N, Cannell P, Mikhael JR, Butcher BE, Prince HM.

Intern Med J. 2009 May;39(5):290-5. doi: 10.1111/j.1445-5994.2008.01738.x. Epub 2008 Jun 28.

PMID:
19371392
13.

A phase II study of bortezomib in mantle cell lymphoma: the National Cancer Institute of Canada Clinical Trials Group trial IND.150.

Belch A, Kouroukis CT, Crump M, Sehn L, Gascoyne RD, Klasa R, Powers J, Wright J, Eisenhauer EA.

Ann Oncol. 2007 Jan;18(1):116-21. Epub 2006 Sep 13.

14.

Single-agent bortezomib in previously untreated multiple myeloma: efficacy, characterization of peripheral neuropathy, and molecular correlations with response and neuropathy.

Richardson PG, Xie W, Mitsiades C, Chanan-Khan AA, Lonial S, Hassoun H, Avigan DE, Oaklander AL, Kuter DJ, Wen PY, Kesari S, Briemberg HR, Schlossman RL, Munshi NC, Heffner LT, Doss D, Esseltine DL, Weller E, Anderson KC, Amato AA.

J Clin Oncol. 2009 Jul 20;27(21):3518-25. doi: 10.1200/JCO.2008.18.3087. Epub 2009 Jun 15.

15.

Bortezomib is active in patients with untreated or relapsed Waldenstrom's macroglobulinemia: a phase II study of the National Cancer Institute of Canada Clinical Trials Group.

Chen CI, Kouroukis CT, White D, Voralia M, Stadtmauer E, Stewart AK, Wright JJ, Powers J, Walsh W, Eisenhauer E; National Cancer Institute of Canada Clinical Trials Group.

J Clin Oncol. 2007 Apr 20;25(12):1570-5. Epub 2007 Mar 12.

16.

Safety and efficacy of bortezomib and melphalan combination in patients with relapsed or refractory multiple myeloma: updated results of a phase 1/2 study after longer follow-up.

Berenson JR, Yang HH, Vescio RA, Nassir Y, Mapes R, Lee SP, Wilson J, Yellin O, Morrison B, Hilger J, Swift R.

Ann Hematol. 2008 Aug;87(8):623-31. doi: 10.1007/s00277-008-0501-0. Epub 2008 May 8.

PMID:
18463870
17.

Single-agent lenalidomide in patients with mantle-cell lymphoma who relapsed or progressed after or were refractory to bortezomib: phase II MCL-001 (EMERGE) study.

Goy A, Sinha R, Williams ME, Kalayoglu Besisik S, Drach J, Ramchandren R, Zhang L, Cicero S, Fu T, Witzig TE.

J Clin Oncol. 2013 Oct 10;31(29):3688-95. doi: 10.1200/JCO.2013.49.2835. Epub 2013 Sep 3.

18.

Phase I/II trial assessing bortezomib and melphalan combination therapy for the treatment of patients with relapsed or refractory multiple myeloma.

Berenson JR, Yang HH, Sadler K, Jarutirasarn SG, Vescio RA, Mapes R, Purner M, Lee SP, Wilson J, Morrison B, Adams J, Schenkein D, Swift R.

J Clin Oncol. 2006 Feb 20;24(6):937-44. Epub 2006 Jan 17.

19.

[Bortezomib in relapsed or refractory multiple myeloma: results in a cohort of 39 patients].

Cánovas Fernández A, Alonso Alonso JJ, Barreiro García JG, Aguirre Errasti C.

Rev Clin Esp. 2008 Apr;208(4):187-92. Spanish.

PMID:
18381003
20.

Treatment of relapsed or refractory Waldenström's macroglobulinemia with bortezomib.

Dimopoulos MA, Anagnostopoulos A, Kyrtsonis MC, Castritis E, Bitsaktsis A, Pangalis GA.

Haematologica. 2005 Dec;90(12):1655-8.

Items per page

Supplemental Content

Write to the Help Desk